Other targets include ENPP3 and CD3 via XmAb819 in advanced clear cell RCC (NCT05433142), HER2 and HER3 by MCLA-128 (zenocutuxumab) in patients with RCC or prostate cancer (NCT04100694), and PD-L1 and CD27 via CDX-527, a tetravalent PD-L1 × CD27 IgG1-scFv BsAb in patients with advanced malignancies, including RCC and bladder urothelial carcinoma (NCT04440943). Here, CD27 is linked to renal cell carcinoma.